Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis
Advanced gastric and gastroesophageal junction cancer (G/GEJC) poses significant therapeutic challenges. Immune checkpoint inhibitors, particularly targeting programmed cell death ligand-1 (PD-L1), have emerged as promising agents to enhance patient outcomes. This meta-analysis evaluates the efficac...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2024-10-01
|
| Series: | Contemporary Oncology |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Comparative-efficacy-of-programmed-death-ligand-1-inhibition-and-chemotherapy-in-advanced-gastric-or-gastroesophageal-junction-cancer-with-combined-positive-score-a-meta-analysis,3,54979,1,1.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584807542947840 |
|---|---|
| author | Zakari Shaibu Fumeng Yang Liu Ting Lily Dzidula Amina Elmi Yusuf Zhi-hong Chen Wei Zhu |
| author_facet | Zakari Shaibu Fumeng Yang Liu Ting Lily Dzidula Amina Elmi Yusuf Zhi-hong Chen Wei Zhu |
| author_sort | Zakari Shaibu |
| collection | DOAJ |
| description | Advanced gastric and gastroesophageal junction cancer (G/GEJC) poses significant therapeutic challenges. Immune checkpoint inhibitors, particularly targeting programmed cell death ligand-1 (PD-L1), have emerged as promising agents to enhance patient outcomes. This meta-analysis evaluates the efficacy of PD-L1 inhibitors compared to chemotherapy in patients with advanced G/GEJC characterised by varying combined positive scores (CPS). We systematically searched PubMed, Google Scholar, and Web of science for clinical trial studies comparing PD-L1 inhibitors and chemotherapy in CPS-positive patients, focusing on studies published up to 10 April 2023. Studies were evaluated with risk of bias tools. The primary clinical endpoint analysed in this study was overall survival (OS), and the secondary endpoint was progression-free survival (PFS). This study is registered with Prospero (CRD42023495607). A total of 10 studies comprising 4522 participants were included. Our analysis revealed no statistically significant difference in CPS values between PD-L1 inhibitors and chemotherapy groups (≥ 1 : 1.03 [95% CI: 0.86–1.24], ≤ 1 : 0.92 [95% CI: 0.77–1.11]). However, the pooled hazard ratio for OS favoured PD-L1 inhibitors (hazard ratios – HR, 0.83, [95% CI: 0.78–0.88] and p < 0.00001), while PFS was better after chemotherapy (HR 1.28, [95% CI: 1.04–1.58], p = 0.02). Program death ligand-1 inhibitors improve OS, while chemotherapy enhances PFS in advanced G/GEJC, warranting further investigation into the impact of CPS on treatment outcomes. |
| format | Article |
| id | doaj-art-9c7511f5e9cc4dc7ab0ad502fc265566 |
| institution | Kabale University |
| issn | 1428-2526 1897-4309 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Contemporary Oncology |
| spelling | doaj-art-9c7511f5e9cc4dc7ab0ad502fc2655662025-01-27T11:19:21ZengTermedia Publishing HouseContemporary Oncology1428-25261897-43092024-10-0128318319010.5114/wo.2024.14410754979Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysisZakari ShaibuFumeng YangLiu TingLily DzidulaAmina Elmi YusufZhi-hong ChenWei ZhuAdvanced gastric and gastroesophageal junction cancer (G/GEJC) poses significant therapeutic challenges. Immune checkpoint inhibitors, particularly targeting programmed cell death ligand-1 (PD-L1), have emerged as promising agents to enhance patient outcomes. This meta-analysis evaluates the efficacy of PD-L1 inhibitors compared to chemotherapy in patients with advanced G/GEJC characterised by varying combined positive scores (CPS). We systematically searched PubMed, Google Scholar, and Web of science for clinical trial studies comparing PD-L1 inhibitors and chemotherapy in CPS-positive patients, focusing on studies published up to 10 April 2023. Studies were evaluated with risk of bias tools. The primary clinical endpoint analysed in this study was overall survival (OS), and the secondary endpoint was progression-free survival (PFS). This study is registered with Prospero (CRD42023495607). A total of 10 studies comprising 4522 participants were included. Our analysis revealed no statistically significant difference in CPS values between PD-L1 inhibitors and chemotherapy groups (≥ 1 : 1.03 [95% CI: 0.86–1.24], ≤ 1 : 0.92 [95% CI: 0.77–1.11]). However, the pooled hazard ratio for OS favoured PD-L1 inhibitors (hazard ratios – HR, 0.83, [95% CI: 0.78–0.88] and p < 0.00001), while PFS was better after chemotherapy (HR 1.28, [95% CI: 1.04–1.58], p = 0.02). Program death ligand-1 inhibitors improve OS, while chemotherapy enhances PFS in advanced G/GEJC, warranting further investigation into the impact of CPS on treatment outcomes.https://www.termedia.pl/Comparative-efficacy-of-programmed-death-ligand-1-inhibition-and-chemotherapy-in-advanced-gastric-or-gastroesophageal-junction-cancer-with-combined-positive-score-a-meta-analysis,3,54979,1,1.htmlgastric cancer gastroesophageal adenocarcinoma immune checkpoint inhibitors chemotherapy survival immunotherapy |
| spellingShingle | Zakari Shaibu Fumeng Yang Liu Ting Lily Dzidula Amina Elmi Yusuf Zhi-hong Chen Wei Zhu Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis Contemporary Oncology gastric cancer gastroesophageal adenocarcinoma immune checkpoint inhibitors chemotherapy survival immunotherapy |
| title | Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis |
| title_full | Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis |
| title_fullStr | Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis |
| title_full_unstemmed | Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis |
| title_short | Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis |
| title_sort | comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score a meta analysis |
| topic | gastric cancer gastroesophageal adenocarcinoma immune checkpoint inhibitors chemotherapy survival immunotherapy |
| url | https://www.termedia.pl/Comparative-efficacy-of-programmed-death-ligand-1-inhibition-and-chemotherapy-in-advanced-gastric-or-gastroesophageal-junction-cancer-with-combined-positive-score-a-meta-analysis,3,54979,1,1.html |
| work_keys_str_mv | AT zakarishaibu comparativeefficacyofprogrammeddeathligand1inhibitionandchemotherapyinadvancedgastricorgastroesophagealjunctioncancerwithcombinedpositivescoreametaanalysis AT fumengyang comparativeefficacyofprogrammeddeathligand1inhibitionandchemotherapyinadvancedgastricorgastroesophagealjunctioncancerwithcombinedpositivescoreametaanalysis AT liuting comparativeefficacyofprogrammeddeathligand1inhibitionandchemotherapyinadvancedgastricorgastroesophagealjunctioncancerwithcombinedpositivescoreametaanalysis AT lilydzidula comparativeefficacyofprogrammeddeathligand1inhibitionandchemotherapyinadvancedgastricorgastroesophagealjunctioncancerwithcombinedpositivescoreametaanalysis AT aminaelmiyusuf comparativeefficacyofprogrammeddeathligand1inhibitionandchemotherapyinadvancedgastricorgastroesophagealjunctioncancerwithcombinedpositivescoreametaanalysis AT zhihongchen comparativeefficacyofprogrammeddeathligand1inhibitionandchemotherapyinadvancedgastricorgastroesophagealjunctioncancerwithcombinedpositivescoreametaanalysis AT weizhu comparativeefficacyofprogrammeddeathligand1inhibitionandchemotherapyinadvancedgastricorgastroesophagealjunctioncancerwithcombinedpositivescoreametaanalysis |